Clinical Trial Update: A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) [Phase 2]

View source ↗

Summary

Phase 2 study update for participants who previously took ASTX727 (oral decitabine/cedazuridine) that is currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• ASTX727 (cedazuridine/decitabine)

Snippet

Sponsor: Taiho Oncology, Inc. | Conditions: Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 2 | Status: ENROLLING_BY_INVITATION